MBRX
MBRX clinical trials: Moleculin Biotech, Inc.
Every trial on ClinicalTrials.gov where Moleculin Biotech, Inc. is the lead sponsor or a listed collaborator, the trials it leads first, each labelled Lead or Collaborator. Phase, status and dates as registered.
- 9
- Trials linked
- 8
- As lead sponsor
- 1
- As collaborator
- 0
- Primary completions as lead sponsor, next 90 days
MBRX on the catalyst calendar · MBRX registry changes
- Primary completion Aug 2029Sponsor estimatePhase 2/Phase 3NCT06788756L-Annamycin for Injection in Combination With Cytarabine Injection as Second Line Therapy for Remission Induction in Adult Subjects With...Moleculin Biotech, Inc. · Acute Myeloid Leukaemia (AML)RecruitingMBRXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Aug 2, 2023ActualPhase 1/Phase 2NCT05319587Study of Liposomal Annamycin in Combination With Cytarabine for the Treatment of Subjects With Acute Myeloid Leukemia (AML)Moleculin Biotech, Inc. · Leukemia, Myeloid, AcuteCompletedMBRXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Sep 29, 2022ActualPhase 1/Phase 2NCT04887298Study of Liposomal Annamycin for the Treatment of Subjects with Soft-Tissue Sarcomas (STS) with Pulmonary MetastasesMoleculin Biotech, Inc. · Sarcoma,Soft TissueCompletedMBRXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Oct 24, 2022ActualPhase 1NCT05195723Study to Assess the Safety and Pharmacokinetics of WP1122 in Healthy VolunteersMoleculin Biotech, Inc. · Healthy VolunteerCompletedMBRXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Feb 8, 2022ActualPhase 1/Phase 2NCT03388749Study of Liposomal Annamycin for the Treatment of Subjects With Acute Myeloid Leukemia (AML)Moleculin Biotech, Inc. · Leukemia, Myeloid, AcuteCompletedMBRXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jan 14, 2020ActualPhase 1/Phase 2NCT03315039Study of Liposomal Annamycin for the Treatment of Subjects With Acute Myeloid Leukemia (AML)Moleculin Biotech, Inc. · Leukemia, Myeloid, AcuteCompletedMBRXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Nov 15, 2019ActualPhase 1NCT04702503Study of WP1220 for the Treatment of Adult Subjects With Cutaneous T-Cell Lymphoma (CTCL)Moleculin Biotech, Inc. · Cutaneous T-Cell Lymphoma/Mycosis FungoidesCompletedMBRXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Aug 2013ActualPhase 2NCT01826201Paired Psoriasis Lesion, Comparative, Study to Evaluate MOL4239 in PsoriasisMoleculin, LLC · PsoriasisCompletedMBRXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 27, 2027Sponsor estimatePhase 2NCT05879250WP1066 and Radiation Therapy in Treating Patients With Newly Diagnosed GlioblastomaNorthwestern University · Glioblastoma, IDH-WildtypeRecruitingMBRXCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
Enrollment, interventions and the start and completion dates are locked on 9 rows here. Included with TrialScanner ($9.99 a month) and Signal8 Pro.
Unlock with TrialScanner